Detalhe da pesquisa
1.
The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium.
Am Heart J
; 202: 104-108, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29920452
2.
Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium.
Am Heart J
; 170(1): 23-35, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26093861
3.
Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
Am Heart J
; 219: 1-8, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707323
4.
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.
Am Heart J
; 165(4): 477-88, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537963
5.
The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development.
Am Heart J
; 165(4): 489-500, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537964
6.
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.
Am Heart J
; 164(6): 846-55, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23194484
7.
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
Am Heart J
; 162(5): 900-6, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22093207
8.
Albuminuria in chronic heart failure: prevalence and prognostic importance.
Lancet
; 374(9689): 543-50, 2009 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19683640
9.
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Eur Heart J
; 30(3): 338-45, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19001475
10.
Feasibility of treating prehypertension with an angiotensin-receptor blocker.
N Engl J Med
; 354(16): 1685-97, 2006 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16537662
11.
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Eur J Heart Fail
; 11(2): 170-7, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19168515
12.
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Eur Heart J
; 29(24): 3022-8, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18987098
13.
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Eur Heart J
; 29(21): 2641-50, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18819960
14.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Eur Heart J
; 29(11): 1377-85, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18413309
15.
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Circulation
; 116(13): 1482-7, 2007 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17724259
16.
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation
; 115(24): 3111-20, 2007 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-17562950
17.
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation
; 116(6): 627-36, 2007 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17638930
18.
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Eur J Heart Fail
; 10(2): 157-63, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18242128
19.
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
J Clin Hypertens (Greenwich)
; 10(6): 436-42, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18550933
20.
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Circulation
; 113(5): 671-8, 2006 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-16461840